Welcome!

News Feed Item

Hard to Treat Depression Patients Recover Completely With Magnetic Therapy

LONDON, July 2, 2013 /PRNewswire/ --


Leading  London Centre  presents first 'real world' UK data, supporting effectiveness of  repetitive Transcranial Magnetic Stimulation  for the treatment of major depression

 

Data from the first 'real-world' treatment audit presented today at The Royal College of Psychiatrists' International Congress 2013 in Edinburgh show that 60% of patients with treatment-resistant depression achieved complete remission (patients report and show no symptoms) when treated with repetitive Transcranial Magnetic Stimulation (rTMS).[1] These data are in-line with results reported in major treatment centres in the US and Canada.

Results from the 'real-world' audit of the first ten UK patients to be treated with rTMS at The London Psychiatry Centre, showed that six of the ten patients assessed achieved no anxiety or depression symptoms at the end of the treatment. Furthermore, one other patient responded to treatment as indicated by a 50% reduction in their depression score. All patients tolerated the treatments well with no significant side effects, with two subjects reporting an occasional mild headache, responding to paracetaomol.[1]  

Dr Rafael Euba, Consultant Psychiatrist at the Centre said, "These data reinforce the body of existing worldwide evidence for rTMS and its proven ability to treat depressed patients who have not responded to drug treatment and/or therapy."

rTMS is a painless and non-invasive method of brain stimulation that relies on electromagnetic induction using an insulated coil placed over the scalp, focused on an area of the brain thought to play a role in mood regulation.[2] Treatment with rTMS is licenced in the UK for adults with depression who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode. For these patients, rTMS provides an effective and pain-free alternative to experience relief from depression, without the side-effects that may be associated with more extreme or chemical alternatives.[3],[4],[5],[6],[7] Offered widely at high profile hospitals and centres in the US, including John Hopkins and Harvard's McLean Hospital, The London Psychiatry Centre is the first and only clinic to offer rTMS treatment in the UK.

One of the patients who recently completed the four week treatment said, "The treatment shifted the way I approach problems and almost blocks my negative way of thinking. I feel like the person I used to be 30 years ago! I've got my brain back!" After two weeks of treatment, not only had the patient stopped taking her medication completely, she no longer felt the dread she woke up with every day and decided to start doing new things, feeling optimistic about her future.

Around one in ten people in the UK suffer from depression at some point in their lifetime, which is over six million people, a number equivalent to the entire population of Scotland. More frequently prescribed treatments don't always work or are not suitable, plus their side-effects can cause weight gain, low sex drive and even heart problems. Up to 70% of people with depression will continue to experience symptoms despite taking medication and/or receiving psychotherapy. This is known as treatment-resistant depression, which is very common.

According to larger international clinical studies, one in two patients who were unresponsive to antidepressant medication experience a significant improvement in their depressive symptoms when treated with rTMS, while 1 in 3 experiences recovery.[6] Patients with resistant depression treated with rTMS also benefited from a shorter recovery time of around 4 weeks. This compares to those trying alternative medications that would typically experience improvements in around 6-9 months, if recognised treatment protocols are followed.

A further 13 patients have been treated with rTMS since the audit presented today, with all of them achieving complete remission within 4 weeks.  An audit of all 23 patients treated showed that 78% of the patients treated at The London Psychiatry Centre with rTMS achieved complete remission, a further 9% improved but did not achieve remission and 13% did not improve.[8]

If you or a person you know would like to find out more information about treatment with rTMS visit The London Psychiatry website at http://www.psychiatrycentre.co.uk.

Notes to Editors

About depression

Around one in ten people in the UK suffer needlessly from depression at some point in their lifetime and it is thought that a large number of people are still undiagnosed. The condition can impact every aspect of a person's life including their ability to work, establish and maintain relationships and their overall quality of life. Depression has also been associated with an increased risk of cardiovascular disease, such as heart attack and stroke.[9],[10],[11],[12]

About rTMS

rTMS is a non-invasive method of brain stimulation that relies on electromagnetic induction using an insulated coil placed over the scalp, focused on an area of the brain thought to play a role in mood regulation.[13] The coil generates brief magnetic pulses, which pass easily and painlessly through the skull and into the brain. The pulses generated are comparable to those generated by magnetic resonance imaging (MRI) machines. When these pulses are administered in rapid succession, it is referred to as "repetitive TMS " or "rTMS", which can produce longer lasting changes in brain activity.[4]Clinical studies have consistently shown that rTMS is effective in treatment-resistant depression,[6],[14],[15],[16],[17],[18],[19],[20].rTMS has been licensed in the UK to treat patients with depression who have not seen a satisfactory response to 2 antidepressants.

In comparison to more extreme alternatives such as electroconvulsive therapy (ECT), rTMS is considerably less invasive, has minimal side effects,[21] and has proven to offer equivalent health benefits.[22] rTMS is therefore seen as a safe middle step in people who do not respond to antidepressants, before considering ECT. In the US, rTMS is offered as a standard therapy in a number of high profile health clinics including John Hopkins and the Mayo Clinic.  

rTMS treatment is well tolerated and non-invasive, requiring only five sessions per week for between two to  six weeks, sometimes followed by maintenance or top-up treatment 6 -12 months later.[19],[20] Patients also recover faster in around 4 weeks, compared to those who tried different forms of medication, who took between 6-9 months to see significant improvements. Patients don't need to go to hospital to receive treatment with rTMS; the simple procedure is performed in an outpatient clinic.

About  The London Psychiatry Centre

The London Psychiatry Centre offers an integrated and complete service addressing every need associated with mental health. This includes psychiatric, psychological, therapeutic and social aspects of a patient. Consultant Psychiatrists, Psychologists and Psychotherapists along with nutritionists, coaches, personal trainers and therapists are on site to help.

To find out more information about The London Psychiatry, visit the website - http://www.psychiatrycentre.co.uk.

References

1. Euba R, Poster presented at The Royal College of Psychiatrists' International Congress 2013

2. George M, Taylor J, Baron Short E, The expanding evidence base for rTMS treatment of depression, Current Opinion Psychiatry, 2013,26:13-18

3. O'Reardon JP, Solvason HB, Janicak PG, et al.Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62:1208-1216.

4. Demitrack MA, Thase ME. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull 2009; 42:5-38.

5. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 2010; 67:507-516.

6. McDonald WM, Durkalski V, Ball ER, et al.Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety 2011; 28:973-980

7. Mantovani A, Pavlicova M, Avery D, et al.Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. Depress Anxiety 2012; 29:883-890

8. The London Psychiatry Centre data on file

9. Ludescher B, Machann J, Eschweiler GW, Thamer C, Maenz C, Hipp A, Claussen CD, & Schick F (2011). Active depression is associated with regional adiposity in the upper abdomen and the neck. International journal of psychiatry in medicine, 41 (3), 271-80 PMID: 22073766 [http://www.ncbi.nlm.nih.gov/pubmed/22073766 ]

10. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, West DS, Wing RR, Knowler WC, & Look AHEAD Research Group (2010). Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia, 53 (8), 1581-9 PMID: 20422396 [http://www.ncbi.nlm.nih.gov/pubmed/20422396 ]

11. Rutledge T, Linke SE, Krantz DS, Johnson BD, Bittner V, Eastwood JA, Eteiba W, Pepine CJ, Vaccarino V, Francis J, Vido DA, & Merz CN (2009). Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Psychosomatic medicine, 71 (9), 958-64 PMID: 19834049 [http://www.ncbi.nlm.nih.gov/pubmed/19834049 ]

12. Shah AJ, Veledar E, Hong Y, Bremner JD, & Vaccarino V (2011). Depression and history of attempted suicide as risk factors for heart disease mortality in young individuals. Archives of general psychiatry, 68 (11), 1135-42 PMID: 22065529 [http://www.ncbi.nlm.nih.gov/pubmed/22065529 ]

13. George M, Taylor J, Baron Short E, The expanding evidence base for rTMS treatment of depression, Current Opinion Psychiatry, 2013,26:13-18

14. Li CT, Wang SJ, Hirvonen J, et al. Antidepressant mechanism of add-on repetitive transcranial magnetic stimulation in medication-resistant depression using cerebral glucose metabolism. J Affect Disord. 2010, 127(1-3):219-29

15. Blumberger DM, Mulsant BH, Fitzgerald PB, et al. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. World J Biol Psychiatry. 2012;13(6):423-35

16. Fitzgerald PB, Hoy K, Gunewardene R, et al. A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression. Psychol Med. 2010;41:1187-1196

17. Galletly C, Gill S, Clarke P, Burton C, Fitzgerald PB. A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments? Psychol Med. Sep 13 2011:1-8.

18. Holtzheimer PE, 3rd, McDonald WM, Mufti M, et al. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety. Oct 2010;27(10):960-963.

19. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587-96.

20. Connolly KR, Helmer A, Cristancho MA, Cristancho P, O'Reardon JP. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012;73(4):e567-73.

21. Eranti S, Mogg, et al. [http://www.ncbi.nlm.nih.gov/pubmed/17202547 ] A Randomized, Controlled Trial with 6-Month Follow-Up of Repetitive Transcranial Magnetic Stimulation and Electroconvulsive Therapy for Severe Depression". American Journal of Psychiatry, 2007164 (1): 73-81

22. Coverage Policy Analysis: Repetitive Transcranial Magnetic Stimulation (rTMS), The New England Comparative Effectiveness Public Advisory Council, completed by: The Institute for Clinical and Economic Review. June 2012

SOURCE The London Psychiatry Centre

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change the...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
SYS-CON Events announced today that IoT Now has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
Updating DevOps to the latest production data slows down your development cycle. Probably it is due to slow, inefficient conventional storage and associated copy data management practices. In his session at @DevOpsSummit at 20th Cloud Expo, Dhiraj Sehgal, in Product and Solution at Tintri, will talk about DevOps and cloud-focused storage to update hundreds of child VMs (different flavors) with updates from a master VM in minutes, saving hours or even days in each development cycle. He will also...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, SSL, peer-to-peer, mob...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
With billions of sensors deployed worldwide, the amount of machine-generated data will soon exceed what our networks can handle. But consumers and businesses will expect seamless experiences and real-time responsiveness. What does this mean for IoT devices and the infrastructure that supports them? More of the data will need to be handled at - or closer to - the devices themselves.
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it m...
The financial services market is one of the most data-driven industries in the world, yet it’s bogged down by legacy CPU technologies that simply can’t keep up with the task of querying and visualizing billions of records. In his session at 20th Cloud Expo, Jared Parker, Director of Financial Services at Kinetica, will discuss how the advent of advanced in-database analytics on the GPU makes it possible to run sophisticated data science workloads on the same database that is housing the rich inf...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.